What's Happening?
Silexion Therapeutics has initiated the GMP clinical supply manufacturing of SIL204, an RNA interference therapy targeting KRAS-driven pancreatic cancer. The manufacturing is in collaboration with Catalent at its European center of excellence. The Tel
Aviv Sourasky Medical Center's Helsinki Ethics Committee has approved the Phase 2/3 trial, marking a significant milestone for Silexion. The trial will evaluate SIL204 in combination with standard chemotherapy, using a dual-route administration strategy. This development follows the Israeli Ministry of Health's approval and a Clinical Trial Application submission in Germany.
Why It's Important?
The advancement of SIL204 into Phase 2/3 trials represents a critical step in addressing KRAS-driven pancreatic cancer, a condition with limited treatment options. Silexion's innovative approach could potentially improve outcomes for patients with this aggressive cancer type. The collaboration with Catalent and regulatory approvals in Israel and Germany highlight the company's strategic progress and readiness to enter clinical trials. Success in these trials could lead to a new therapeutic option for pancreatic cancer, impacting patient care and positioning Silexion as a key player in oncology therapeutics.
